2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Mitochondrial Metabolism

Mitochondrial Metabolism

Mitochondrial Metabolism

Related Products

PDF 1.28 MB

Mitochondria use multiple carbon fuels to produce ATP and metabolites, including pyruvate, which is generated from glycolysis; amino acids such as glutamine; and fatty acids. These carbon fuels feed into the TCA cycle in the mitochondrial matrix to generate the reducing equivalents NADH and FADH2, which deliver their electrons to the electron transport chain. Mitochondria are complex organelles that play an important role in many facets of cellular function, from metabolism to immune regulation and cell death. Mitochondria are actively involved in a wide variety of cellular processes and molecular interactions, such as calcium buffering, lipid flux, and intracellular signaling. It is increasingly recognized that mitochondrial dysfunction is a hallmark of many diseases such as obesity/diabetes, cancer, cardiovascular and neurodegenerative diseases. Mitochondrial metabolism is a key determinant of tumor progression by impacting on functions such as epithelial-to-mesenchymal transition. Mitochondrial metabolism and derived oncometabolites shape the epigenetic landscape to alter aggressiveness features of cancer cells. Changes in mitochondrial metabolism are relevant for the survival of tumors in response to therapy.

Cat. No. Product Name Effect Purity
  • HY-B1756
    Rotenone
    		Inhibitor 99.65%
    Rotenone is a mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
  • HY-100941
    CCCP
    		Inhibitor 99.83%
    CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
  • HY-100410
    FCCP
    		99.51%
    FCCP is an uncoupler of oxidative phosphorylation (OXPHOS) in mitochondria. FCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
  • HY-D1055
    MitoSOX Red
    MitoSOX Red is a novel fluorescent probe that specifically targets mitochondria in living cells with cell membrane permeability. MitoSOX Red enters the mitochondria, it is oxidized by superoxide, but not by other ROS or RNS generating systems. MitoSOX Red then binds to intramitochondrial nucleic acids, producing strong red fluorescence. MitoSOX Red can be used as a fluorescent indicator to specifically detect superoxide. Additionally, Superoxide dismutase (SOD) prevents the oxidation of MitoSOX Red.
    Excitation/emission wavelength: 396/610 nm.
  • HY-112879
    Mito-TEMPO
    		98.35%
    Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.
  • HY-153040
    Bach1-IN-1
    		Inhibitor 99.67%
    Bach1-IN-1 (compound 236) is a potent Bach1 inhibitor. Bach1 is a transcription factor of the cap'n'collar type alkaline region leucine zipper factor family (CNC-bZip) that regulates mitochondrial metabolism and reduces glucose utilization. Bach1-IN-1 can be used for research in psoriasis, multiple sclerosis, and COPD.
  • HY-139577A
    Ninerafaxstat trihydrochloride
    Ninerafaxstat (IMB-1018972) trihydrochloride is a cardiac mitotrope agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase).
  • HY-136093B
    Lixumistat
    		Inhibitor
    Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus.
  • HY-15475
    UK-5099
    		Inhibitor 99.96%
    UK-5099 (PF-1005023) is a potent inhibitor of the mitochondrial pyruvate carrier (MPC). UK-5099 (PF-1005023) inhibits pyruvate-dependent O2 consumption with an IC50 of 50 nM.
  • HY-W008719
    MPP+ iodide
    		Inhibitor 99.93%
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT).
  • HY-15453
    Devimistat
    		Inhibitor 99.59%
    Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
  • HY-112037
    IACS-010759
    		Inhibitor 99.60%
    IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research.
  • HY-B0356
    Ciprofloxacin
    		Inhibitor 99.86%
    Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-100004
    Fumarate hydratase-IN-1
    		Inhibitor 99.37%
    Fumarate hydratase-IN-1 (compound 2) is a cell-permeable fumarate hydratase inhibitor. Fumarate hydratase-IN-1 has antiproliferative activity against several cancer cell lines with a mean IC50 of 2.2 μM.
  • HY-123986
    CTPI-2
    		Inhibitor 99.90%
    CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.
  • HY-15206
    Glibenclamide
    		99.70%
    Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. Glibenclamide can induce autophagy.
  • HY-B0486
    Lonidamine
    		Inhibitor 99.73%
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
  • HY-P0025
    NIM811
    		Inhibitor 99.52%
    NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
  • HY-B1334A
    Perhexiline maleate
    		Modulator 99.26%
    Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.
  • HY-134539
    IMT1
    		Inhibitor 98.54%
    IMT1 is a first-in-class specific and noncompetitive human mitochondrial RNA polymerase (POLRMT) inhibitor. IMT1 causes a conformational change of POLRMT, which blocks substrate binding and transcription in a dose-dependent way in vitro. IMT1 reduces deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in a marked depletion of cellular amino acid levels. IMT1 has the potential for mitochondrial transcription disorders related diseases.
Cat. No. Product Name / Synonyms Application Reactivity